Video | Agriculture | Confidence | Economy | Energy | Employment | Finance | Media | Property | RBNZ | Science | SOEs | Tax | Technology | Telecoms | Tourism | Transport | Search

 

EvoGenix completes $A5 million capital raising

EvoGenix completes $A5 million capital raising


Antibody therapeutics company EvoGenix Limited (ASX:EGX) today announced the successful completion of a $A5 million capital raising through a share placement to institutional and sophisticated investors.

The share placement is for 10 million shares at an issue price of $0.50 per share.

The placement included investments both from existing shareholders and from a number of other institutional investors with expertise in the biotechnology sector.

EvoGenix CEO and Managing Director Merilyn Sleigh commented that the additional capital will be used primarily to accelerate development of the company’s product pipeline with particular emphasis on anti-cancer antibody drugs under development.

Dr Sleigh noted “EvoGenix has been able to access two very exciting prospects for novel cancer treatments through agreements announced this year with the University of Massachusetts, USA and the US National Institutes of Health. These offer new approaches to treatment of cancers where an effective drug could be expected to achieve more than a billion dollars in annual sales. Our work during the next 12 months will be focused on confirming the effectiveness of these potential treatments in our pre-clinical studies, accelerating products through to the clinical testing phase.”

Lodge Corporate Services Pty Ltd acted as Adviser and Lead Manager for the placement.

Details of the raising

EvoGenix will issue 10 million new shares as a result of the placement. This represents less than 15% of the company’s total issued capital, allowing the issue to proceed under Rule 7.1 of the ASX listing rules without additional shareholder approval. Application for listing of the new shares will be made in the near future.

About EvoGenix

EvoGenix Limited (ASX:EGX) has established leading technology capabilities for creating high value antibody and protein-based therapeutics. The company exploits its capabilities through technology collaborations with partner companies, and by development in-house of a succession of wholly-owned antibody and protein products.

Antibodies are natural proteins designed to attack, block and remove unwanted materials
from the body. Antibodies are usually first made in animals such as mice or rats, and in their initial state are unsuitable for use in patients, because the foreign protein is rapidly rejected by the human immune system.

The EvoGenix technology can convert a research-stage antibody into a high potency therapeutic suitable for long term administration to patients. This is a key value-creating step in antibody development.

EvoGenix is progressively building company value by assembling a portfolio of revenues from technology collaborations using its unique technology capabilities. Multi project collaborations with GlaxoSmithKline and Australia’s CSL Limited have been announced in the past 12 months.

At the same time EvoGenix is advancing its internal product pipeline, with current products aimed at the treatment of osteoporosis, lung cancer, melanoma and respiratory infections. Generally, these will be out-licensed prior to the clinical stage to meet the existing high demand for new biotherapeutic products in the pharmaceutical industry.

Ends

© Scoop Media

 
 
 
Business Headlines | Sci-Tech Headlines

 

Mycoplasma Bovis: More Properties Positive

One of the latest infected properties is in the Hastings district, the other three are within a farming enterprise in Winton. The suspect property is near Ashburton. More>>

ALSO:

Manawatū Gorge Alternative: More Work Needed To Choose Route

“We are currently working closely and in partnership with local councils and other stakeholders to make the right long-term decision. It’s vital we have strong support on the new route as it will represent a very significant long-term investment and it will need to serve the region and the country for decades to come.” More>>

ALSO:

RBNZ: Super Fund Chief To Be New Reserve Bank Governor

Adrian Orr has been appointed as Reserve Bank Governor effective from 27 March 2018, Finance Minister Grant Robertson says. More>>

ALSO:

ScoopPro: Helping PR Professionals Get More Out Of Scoop

Scoop.co.nz has been a fixture of New Zealand’s news and Public Relations infrastructure for over 18 years. However, without the financial assistance of those using Scoop in a professional context in key sectors such as Public Relations and media, Scoop will not be able to continue this service... More>>

Insurance: 2017 Worst Year On Record For Weather-Related Losses

The Insurance Council of New Zealand (ICNZ) announced today that 2017 has been the most expensive year on record for weather-related losses, with a total insured-losses value of more than $242 million. More>>

ALSO: